8-K
filed June 1, 2026, 8:30 AM ET
ticker CHRS
CIK 0001512762
other
confidence high
sentiment neutral
materiality 0.15
Coherus Oncology annual meeting results: directors elected, equity plan approved, option repricing narrowly passes
Coherus Oncology, Inc.
- Class III directors Dennis M. Lanfear and Mats L. Wahlström re-elected with 82.5M and 81.2M votes for each, respectively.
- Ratification of Ernst & Young as independent auditor approved by 121.1M votes for, 1.5M against.
- Say-on-pay advisory vote on executive compensation passed with 73.3M for, 10.9M against, 4.8M abstain.
- Stock option repricing proposal (Prop 4) approved in close vote: 46.0M for, 45.4M against, 0.4M abstain.
- Increase in shares reserved under Amended 2014 Equity Plan approved: 59.5M for, 24.9M against, 4.6M abstain.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Coherus Oncology, Inc. shareholders approved Advisory vote to approve compensation of named executive officers (Say-on-Pay) at the 2026-05-27 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2026-05-27
Exact text from the filing
The Company’s stockholders approved a non-binding, advisory resolution to approve the compensation of the Company’s named executive officers (a “Say-on-Pay” vote).
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Coherus Oncology, Inc. shareholders approved Approval of increase in number of shares of common stock reserved for issuance under the Amended and Restated 2014 Equity Incentive Award Plan at the 2026-05-27 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2026-05-27
Exact text from the filing
The Company’s stockholders approved an increase in the number of shares of common stock reserved for issuance under the Amended and Restated 2014 Equity Incentive Award Plan.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Coherus Oncology, Inc. shareholders approved Election of Class III directors at the 2026-05-27 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-05-27
Exact text from the filing
The Company’s stockholders elected by a majority of votes cast each of the Class III director nominees below, Dennis M. Lanfear and Mats L. Wahlström, to the Board of Directors of the Company to hold office until the 2029 annual meeting of stockholders or until their successors are elected.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Coherus Oncology, Inc. shareholders approved Ratification of selection of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-05-27 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-05-27
Exact text from the filing
The Company’s stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Coherus Oncology, Inc. shareholders approved Approval of reduction in exercise price of certain outstanding stock options at the 2026-05-29 meeting.
- Outcome
- passed
- Meeting
- 2026-05-29
Exact text from the filing
The Company’s stockholders approved the reduction in the exercise price of certain outstanding stock options.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.